Despite many years of research, no biomarkers for stroke are available to use in clinical
practice. Progress in high-throughput technologies has provided new opportunities to …

Ischemic stroke (IS) is a multifactorial and heterogeneous neurological disorder with high
rate of death and long-term impairment. Despite years of studies, there are still no stroke …

Stroke remains a leading cause of death and disability, with limited therapeutic options and
suboptimal tools for diagnosis and prognosis. High throughput technologies such as …

Oxygen glucose deprivation (OGD) of brain cells is the commonest in vitro model of ischemic
stroke that is used extensively for basic and preclinical stroke research. Protein mass …

Because of its rapid progression and frequently poor prognosis, stroke is the third major
cause of death in Europe and the first one in China. Many independent studies …

Neuroproteomics, an emerging field at the intersection of neuroscience and proteomics, has
garnered significant attention in the context of neurotrauma research. Neuroproteomics …

Background and Objectives Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease of unknown etiology and poorly understood pathophysiology. There is no specific …

Background Loss of motor neurons in amyotrophic lateral sclerosis (ALS) leads to
progressive paralysis and death. Dysregulation of thousands of RNA molecules with roles in …

The use of proteomics in human studies investigating stroke and myocardial infarction (MI)
has been increasing, prompting a review of the literature. This revealed proteinaceous …

It remains unclear to what extent tumor heterogeneity impacts on protein biomarker
discovery. Here, we quantified proteome intra-tissue heterogeneity (ITH) based on a multi …